Zymeworks (ZYME) to Offer Common Stock and Pre-Funded Warrant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
January 21, 2020 4:08 PM ESTVANCOUVER, British Columbia---(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME) (Zymeworks or the Company), a clinicalstage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the Canadian Supplement) to its Canadian short form base shelf prospectus dated November 18, 2019 (the Base Prospectus) in connection with an offering of its common shares and, in lieu of common shares to a certain investor, pre-funded warrants to purchase its common shares (the Offering). The Canadian Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Canada. A preliminary... More
